Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891020281> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2891020281 endingPage "5108" @default.
- W2891020281 startingPage "5101" @default.
- W2891020281 abstract "Background/Aim: The present study was designed to identify conditions that would increase the sensitivity of resistant cancer cells to anti-mitotic drugs. Materials and Methods: Previously, we showed that KBV20C cancer cells highly resistant to Halaven® (HAL) were sensitized by co-treatment with fluphenazine (FLU). In this study, we found that low doses of aripiprazole (ARI), another antipsychotic drug, sensitized HAL-resistant KBV20C cancer cells. We then investigated the mechanisms and roles of ARI in the sensitization of HAL-treated KBV20C cancer cells. Results: First-generation P-glycoprotein (P-gp) inhibitor verapamil required a dose that was nearly four-fold higher than that of ARI for P-gp inhibition, which suggested that ARI had a high specificity for P-gp binding to prevent efflux of anti-mitotic drugs. ARI was also found to sensitize HAL-treated KBV20C cells at a low dose, approximately 4-fold lower than that of verapamil. Co-treatment of ARI with another anti-mitotic drug, vincristine, also increased the sensitization of KBV20C cells. ARI caused a reduction in cell viability, increased G<sub>2</sub> arrest, and up-regulated expression of the DNA damage protein, pH2AX, when co-treated with HAL. Moreover, G<sub>2</sub> phase arrest and apoptosis in HAL-ARI co-treated cells resulted from the up-regulation of retinoblastoma protein, reduced extracellular signal-regulated kinase pathway activity, and down-regulation of cell division cyclin protein. Conclusion: Cancer cells that are highly resistant to HAL can be sensitized with the antipsychotic drug, ARI, which exerts specific P-gp inhibitory effects at a low dose." @default.
- W2891020281 created "2018-09-27" @default.
- W2891020281 creator A5037370901 @default.
- W2891020281 creator A5052433739 @default.
- W2891020281 creator A5055461491 @default.
- W2891020281 creator A5078731540 @default.
- W2891020281 creator A5091003200 @default.
- W2891020281 date "2018-09-01" @default.
- W2891020281 modified "2023-10-14" @default.
- W2891020281 title "Low Doses of the Anti-psychotic Drug Aripiprazole Have Strong P-gp-inhibitory Activity and Sensitize Anti-mitotic Drug-resistant Cancer Cells" @default.
- W2891020281 doi "https://doi.org/10.21873/anticanres.12830" @default.
- W2891020281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30194155" @default.
- W2891020281 hasPublicationYear "2018" @default.
- W2891020281 type Work @default.
- W2891020281 sameAs 2891020281 @default.
- W2891020281 citedByCount "12" @default.
- W2891020281 countsByYear W28910202812020 @default.
- W2891020281 countsByYear W28910202812021 @default.
- W2891020281 countsByYear W28910202812022 @default.
- W2891020281 countsByYear W28910202812023 @default.
- W2891020281 crossrefType "journal-article" @default.
- W2891020281 hasAuthorship W2891020281A5037370901 @default.
- W2891020281 hasAuthorship W2891020281A5052433739 @default.
- W2891020281 hasAuthorship W2891020281A5055461491 @default.
- W2891020281 hasAuthorship W2891020281A5078731540 @default.
- W2891020281 hasAuthorship W2891020281A5091003200 @default.
- W2891020281 hasBestOaLocation W28910202811 @default.
- W2891020281 hasConcept C121608353 @default.
- W2891020281 hasConcept C126322002 @default.
- W2891020281 hasConcept C184235292 @default.
- W2891020281 hasConcept C2777292972 @default.
- W2891020281 hasConcept C2780035454 @default.
- W2891020281 hasConcept C55493867 @default.
- W2891020281 hasConcept C71924100 @default.
- W2891020281 hasConcept C86803240 @default.
- W2891020281 hasConcept C93304396 @default.
- W2891020281 hasConcept C95444343 @default.
- W2891020281 hasConcept C96232424 @default.
- W2891020281 hasConcept C98274493 @default.
- W2891020281 hasConceptScore W2891020281C121608353 @default.
- W2891020281 hasConceptScore W2891020281C126322002 @default.
- W2891020281 hasConceptScore W2891020281C184235292 @default.
- W2891020281 hasConceptScore W2891020281C2777292972 @default.
- W2891020281 hasConceptScore W2891020281C2780035454 @default.
- W2891020281 hasConceptScore W2891020281C55493867 @default.
- W2891020281 hasConceptScore W2891020281C71924100 @default.
- W2891020281 hasConceptScore W2891020281C86803240 @default.
- W2891020281 hasConceptScore W2891020281C93304396 @default.
- W2891020281 hasConceptScore W2891020281C95444343 @default.
- W2891020281 hasConceptScore W2891020281C96232424 @default.
- W2891020281 hasConceptScore W2891020281C98274493 @default.
- W2891020281 hasIssue "9" @default.
- W2891020281 hasLocation W28910202811 @default.
- W2891020281 hasLocation W28910202812 @default.
- W2891020281 hasOpenAccess W2891020281 @default.
- W2891020281 hasPrimaryLocation W28910202811 @default.
- W2891020281 hasRelatedWork W1980923728 @default.
- W2891020281 hasRelatedWork W1990964652 @default.
- W2891020281 hasRelatedWork W1996171153 @default.
- W2891020281 hasRelatedWork W2032368516 @default.
- W2891020281 hasRelatedWork W2045698890 @default.
- W2891020281 hasRelatedWork W2135538021 @default.
- W2891020281 hasRelatedWork W2400588389 @default.
- W2891020281 hasRelatedWork W3210223225 @default.
- W2891020281 hasRelatedWork W4200052869 @default.
- W2891020281 hasRelatedWork W4285729843 @default.
- W2891020281 hasVolume "38" @default.
- W2891020281 isParatext "false" @default.
- W2891020281 isRetracted "false" @default.
- W2891020281 magId "2891020281" @default.
- W2891020281 workType "article" @default.